ALX ONCOLOGY HOLDINGS INC 8-K

What Happened

• ALX Oncology Holdings, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company issued a press release on February 27, 2026 that summarizes those results; that press release is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: February 27, 2026 (Current Report on Form 8-K).
• Reporting item: Item 2.02 (Results of Operations and Financial Condition); press release incorporated as Exhibit 99.1.
• Period covered: Q4 and full year ended December 31, 2025.
• Signature: Report signed by Harish Shantharam, Chief Financial Officer of ALX Oncology Holdings Inc.

Why It Matters

• This 8-K is the company’s official disclosure of its quarterly and full-year 2025 earnings information (earnings/quarterly results). Investors should review Exhibit 99.1 (the press release) for the detailed revenue, profit/loss, cash position, and any management commentary or guidance.
• Because the 8-K furnishes the press release rather than presents complete financial statements, investors may also want to watch for the company’s subsequent SEC filings (e.g., annual report on Form 10-K) for audited financials and additional context.